'One DS Culture' Goes Global: Daiichi Sankyo's Transformation Journey With PwC

Business'One DS Culture' Goes Global: Daiichi Sankyo's Transformation Journey With PwCByPwC Consulting LLC Contributor,Brand Contributor.for PwC Consulting LLCBRANDVOICEStorytelling and expertise from marketers | Paid ProgramMay 11, 2026, 04:00am EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more. Forbes JapanFollowing the successful launch of a new cancer drug in January 2020, Daiichi Sankyo has leveraged its antibody-drug conjugates (ADCs) to strengthen its global brand recognition. As it evolves into a truly global pharmaceutical company with clear strengths in oncology, how will the company sustain that momentum? Here, Head of Corporate Strategy and Business Portfolio, Atsushi Tsukamoto discusses strategy and leadership with Pluek “Eddie” Viriyahboubpha and Kei Takahashi of PwC Consulting Japan, a consulting partner in this transformation.Japanese Global Pharma Making A Name In Oncology"Eddie” Viriyahboubpha: Since the launch of your new cancer treatment in your fiscal year 2019, Daiichi Sankyo’s global awareness, especially in the United States, seems to have grown significantly. As a global strategy leader, how do you view this change?Atsushi Tsukamoto: You’re right, Daiichi Sankyo never had much brand recognition outside Japan. But during my most recent time in the U.S., even my apartment manager recognized our name. That was a clear sign something had changed. We’re also seeing it in recruitment—oncology professionals are increasingly asking how they can join us.ADCs were once widely viewed as an unpromising technology, but Daiichi Sankyo’s success has revived interest and intensified competition across the industry. Atsushi Tsukamoto, Senior Corporate Officer, Head of Corporate Strategy & Business Portfolio Department, Global Corporate Strategy at Daiichi Sankyo / PhD in Pharmaceuticals DevelopmentForbes JapanThe Next Path To Success: True GlobalKei Takahashi: As...